Skip to main content
. 2023 Oct 4;23:400. doi: 10.1186/s12886-023-03157-z

Table 3.

Clinical outcomes after combination therapy

Outcomes Combination group
Primary outcome
 Improvement in DRSS levels, n (%)
   ≥ 2 steps 27 (44)
   < 2 steps 34 (56)
Secondary outcomes
 NV reduction, n (%) 13 (48)
 BCVA gain ≥ 0.1 logMAR, n (%) 19 (31)
 CMT decrease ≥ 50 μm, n (%) 14 (23)

DRSS diabetic retinopathy severity scale, NV neovascularization, BCVA best-corrected visual acuity, CMT central macular thickness